Effect of a Known P-glycoprotein (P-gp) Inhibitor, Itraconazole, on the Pharmacokinetics (PK) of Engasertib

计划入组 27 人 · 首次发布于 2026 年 9 月 2 日

A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)

计划入组 240 人 · 首次发布于 2026 年 8 月 4 日

Vaderis Launches Global Phase 3 HEROIC Trial of Engasertib for Hereditary Hemorrhagic Telangiectasia

Engasertib Shows Promise in First Controlled Trial for Hereditary Hemorrhagic Telangiectasia

Vaderis Raises $152 Million to Fund Phase 3 Trial of AKT Inhibitor Engasertib in Hereditary Haemorrhagic Telangiectasia